TLR

  • Inhibitory Selectivity
  • Solubility
Catalog No. Product Name Solubility(25°C)
Water DMSO Alcohol
S8562 CA-4948 <1 mg/mL 30 mg/mL <1 mg/mL
S8677 Cu-CPT22 <1 mg/mL 72 mg/mL 9 mg/mL
S7221 GS-9620 <1 mg/mL 1 mg/mL <1 mg/mL
S8133 Resiquimod <1 mg/mL 63 mg/mL 21 mg/mL
S7161 Motolimod (VTX-2337) <1 mg/mL 55 mg/mL 15 mg/mL
Catalog No. Information Product Use Citations Product Validations
S8562New

CA-4948

CA-4948 is a reversible kinase inhibitor that modulates IRAK4 function in both the toll-like receptor (TLR) and interleukin 1 receptor (IL-1R) signaling cascades, and demonstrates pharmacodynamic and antitumor activity in in vitro and in vivo nonclinical models.
S8677New

Cu-CPT22

CU-CPT22 shows dose-dependent inhibitory effects blocking Pam3CSK4-induced TLR1/2 activation with an IC50 of 0.58 ± 0.09 µM while no significant inhibition to TLR2/6. It demonstrates minimal non-specific inhibition against a panel of 10 representative kinases (PDGFRB, MET, DDR2, SRC, MAPK1, PAK1, AKT1, PKC-γ, CAMK1, and PLK4).
S7221

GS-9620

GS-9620 is a potent and selective orally active small molecule agonist of Toll-like receptor 7.
S8133

Resiquimod

Resiquimod is an immune response modifier that acts as a potent TLR 7/8 agonist. Phase 2.

S7161

Motolimod (VTX-2337)

Motolimod (VTX-2337) is a selective and potent Toll-like receptor (TLR) 8 agonist with EC50 of 100 nM, > 50-fold selectivity over TLR7. Phase 2.